A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH(2022)

引用 1|浏览3
暂无评分
摘要
These results can help patients with overactive bladder understand their own chances of treatment success with fesoterodine and can help doctors support their patients on what to expect regarding their specific symptoms and concerns. ▪Toviaz (fesoterodine) is approved to treat the condition that is discussed in this summary. Approval varies from country to country; please check with your local health provider for more details. ▪This summary reports the combined results of 6 studies. The results of individual studies may vary from the combined study results presented here. Individuals should make treatment decisions based on all available evidence. ClinicalTrials.gov NCT number: NCT01302054, NCT01302067, NCT00444925, NCT00611026, NCT00220363, and NCT00138723.
更多
查看译文
关键词
clinical trial, fesoterodine, lay summary, older adult, overactive bladder, plain language summary, quality of life, treatment efficacy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要